Meeting
2019 ASCO Annual Meeting
Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.
Authors
Jeroen Elassaiss-Schaap
Aduro Biotech, Berkeley, CA
Jeroen Elassaiss-Schaap , Peter van Zandvoort , Jeannette Lo , Nitya Nair , Jackie Walling , Parameswaran Hari , William Bensinger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03340883
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8022)
DOI
10.1200/JCO.2019.37.15_suppl.8022
Abstract #
8022
Poster Bd #
348
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.
First Author: Ravi Vij
Poster
2022 ASCO Annual Meeting
CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.
First Author: Sosana Delimpasi
Poster
2022 ASCO Annual Meeting
Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
First Author: Tara L. Lin
Poster
2020 ASCO Virtual Scientific Program
GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.
First Author: Adam D. Cohen